Latest Commercialization News

Atomo Diagnostics has landed a significant $502,000 order for HIV self-tests destined for an African country, underscoring sustained demand for accessible diagnostics in the region.

Amaero Ltd has lowered its FY2026 revenue guidance due to delayed U.S. government contracts but reports strong contracted revenue and a robust cash position heading into 2026.

Vitrafy Life Sciences has entered a 12-month exclusive partnership with IMV Technologies to integrate cryopreservation technologies, securing up to A$930k in fees and milestone payments.

Vitrafy Life Sciences has secured a 12-month exclusive partnership with global animal reproduction leader IMV Technologies to co-develop and commercialise next-generation cryopreservation solutions for farm animals and aquaculture.

Aquirian Limited reports a robust first half of FY26 with revenue up 27.4% and EBITDA more than doubling, driven by strategic facility upgrades and promising joint ventures.

Osteopore Limited has completed the full subscription of Tranche 1 under its A$20 million convertible notes facility, raising an additional A$250,000 to support ongoing business and future projects.

3D Energi has confirmed a new gas discovery at the Charlemont-1 well in Victoria’s Otway Basin, reinforcing the prospectivity of the Charlemont Trend and the potential for increased domestic gas supply.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

Accent Resources NL has withdrawn a previously stated production target for its Magnetite Range Project, clarifying the figure was aspirational and non-compliant with ASX rules. The company continues to advance its flagship magnetite development in Western Australia, highlighting its alignment with green steel demand.

Power Minerals has terminated its joint venture with Navigate Energy on the Rincon Lithium Project, opting to retain full ownership and seek new partners amid a buoyant lithium market.

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

Resolution Minerals reports outstanding high-grade antimony, silver, and gold assay results from rock samples at its Antimony Ridge Mine in Idaho, reinforcing the project's strategic importance in the US critical minerals landscape.